CR11362A - Bisfosfonatos de alquilo de 2 a 5 atomos de carbono-imidazol - Google Patents

Bisfosfonatos de alquilo de 2 a 5 atomos de carbono-imidazol

Info

Publication number
CR11362A
CR11362A CR11362A CR11362A CR11362A CR 11362 A CR11362 A CR 11362A CR 11362 A CR11362 A CR 11362A CR 11362 A CR11362 A CR 11362A CR 11362 A CR11362 A CR 11362A
Authority
CR
Costa Rica
Prior art keywords
imidazol
caromon
bisphosphonates
rent
atoms
Prior art date
Application number
CR11362A
Other languages
English (en)
Inventor
Sven Weiler
Leo Widler
Jean-Michael Rondeau
Simona Cotesta
Wolfgang Jahnke
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39154111&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR11362(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR11362A publication Critical patent/CR11362A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen acidos [(imidazol-1-il)-1-hidroxi-1-fosfono-etil] -fosfonicos sustituidos por alquilo de 2 a 5 atomos de carbono, asi como metodos o procesos para su fabricacion, su uso en la fabricacion de formulaciones farmaceuticas, su uso en el tratamiento de enfermedades, metodos para utilizarlos en el tratamiento de enfermedades, formulaciones farmaceuticas que los abarcan, y/o los compuestos para utilizarse en el tratamiento de enfermedades.
CR11362A 2007-11-30 2010-04-09 Bisfosfonatos de alquilo de 2 a 5 atomos de carbono-imidazol CR11362A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07122016 2007-11-30

Publications (1)

Publication Number Publication Date
CR11362A true CR11362A (es) 2010-06-14

Family

ID=39154111

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11362A CR11362A (es) 2007-11-30 2010-04-09 Bisfosfonatos de alquilo de 2 a 5 atomos de carbono-imidazol

Country Status (24)

Country Link
US (2) US7977323B2 (es)
EP (1) EP2225252B1 (es)
JP (1) JP5244917B2 (es)
KR (1) KR20100092035A (es)
CN (1) CN101835787A (es)
AR (1) AR069437A1 (es)
AU (1) AU2008328797B2 (es)
BR (1) BRPI0819902A2 (es)
CA (1) CA2701516A1 (es)
CL (1) CL2008003545A1 (es)
CO (1) CO6280421A2 (es)
CR (1) CR11362A (es)
EA (1) EA201000860A1 (es)
EC (1) ECSP10010321A (es)
ES (1) ES2386851T3 (es)
IL (1) IL204657A0 (es)
MA (1) MA31895B1 (es)
MX (1) MX2010005786A (es)
NZ (1) NZ584219A (es)
PE (1) PE20091038A1 (es)
TN (1) TN2010000138A1 (es)
TW (1) TW200932248A (es)
WO (1) WO2009068567A1 (es)
ZA (1) ZA201001992B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0910901A2 (pt) * 2008-04-04 2015-09-29 Novartis Ag composição farmacêutica com bisfosfonato
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
HUE034784T2 (en) 2009-07-31 2018-02-28 Gruenenthal Gmbh Crystallization process and bioavailability
WO2011147038A1 (en) 2010-05-28 2011-12-01 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US9290526B2 (en) 2010-05-28 2016-03-22 The Royal Institution For The Advancement Of Learning/Mcgill University Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CN102659840B (zh) * 2012-05-10 2013-08-14 苏州普瑞诺药物技术有限公司 咪唑双膦酸类化合物及其可药用盐及药物用途
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
WO2019076269A1 (zh) 2017-10-16 2019-04-25 清华大学 甲羟戊酸通路抑制剂及其药物组合物
CN112980809B (zh) * 2021-03-17 2023-04-11 云南中烟工业有限责任公司 一种烟草法尼基焦磷酸合酶基因及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3776880D1 (de) 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
CA2101275C (en) * 1991-02-26 1998-08-04 Jocelyn Elaine Mcosker Methods for the treatment of osteoporosis
GB9324143D0 (en) 1993-11-24 1994-01-12 Schering Agrochemicals Ltd Triazole phosphonate pesticides
GB0029018D0 (en) * 2000-11-28 2001-01-10 Strakan Group Plc Dermatological formulations
GB0029111D0 (en) 2000-11-29 2001-01-10 Novartis Ag Organic compounds
US7358361B2 (en) 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2008128056A1 (en) 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
PE20081043A1 (es) 2006-10-05 2008-09-17 Novartis Ag Composicion farmaceutica que comprende bifosfonatos
CA2682231A1 (en) 2007-03-28 2008-10-09 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors

Also Published As

Publication number Publication date
NZ584219A (en) 2012-03-30
BRPI0819902A2 (pt) 2015-05-19
CA2701516A1 (en) 2009-06-04
IL204657A0 (en) 2010-11-30
TW200932248A (en) 2009-08-01
ZA201001992B (en) 2010-12-29
US20110224173A1 (en) 2011-09-15
WO2009068567A1 (en) 2009-06-04
US7977323B2 (en) 2011-07-12
KR20100092035A (ko) 2010-08-19
AU2008328797A1 (en) 2009-06-04
EA201000860A1 (ru) 2010-12-30
CN101835787A (zh) 2010-09-15
EP2225252A1 (en) 2010-09-08
ECSP10010321A (es) 2010-08-31
AU2008328797B2 (en) 2011-11-03
US20090143337A1 (en) 2009-06-04
AR069437A1 (es) 2010-01-20
MX2010005786A (es) 2010-06-09
TN2010000138A1 (en) 2011-09-26
MA31895B1 (fr) 2010-12-01
PE20091038A1 (es) 2009-08-19
ES2386851T3 (es) 2012-09-03
CO6280421A2 (es) 2011-05-20
JP5244917B2 (ja) 2013-07-24
CL2008003545A1 (es) 2009-06-05
JP2011504908A (ja) 2011-02-17
EP2225252B1 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
CR11362A (es) Bisfosfonatos de alquilo de 2 a 5 atomos de carbono-imidazol
UY29004A1 (es) Compuestos derivados sustituídos de ácidos, glicina y alanina; procedimiento para su preparación y uso.
CR20120264A (es) Compuestos
AR063628A1 (es) Compuestos de piridinona utiles para el tratamiento de cancer
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
BRPI0512683A (pt) compostos anti-virais
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
CR20110326A (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
CO6630189A2 (es) Compuestos heterocíclicos de nitrógeno útiles como inhibidores de pde10
PA8841901A1 (es) Compuestos orgánicos
MX337152B (es) Composiciones que comprenden moduladores del receptor de fosfato de esfingosina-1 (s1p).
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
UY33337A (es) DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
CU20120013A7 (es) Derivados de oxacina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
CL2012002487A1 (es) Compuestos derivados de imidazo[1,2-a]pirazina, inhibidores de pde10; composicion farmacéutica que los comprende; proceso para preparar la composicion farmaceutica; utiles para el tratamiento de enfermedades neurológicas, psiquiátricas o metabólicas tales como esquizofrenia, parkinson y diabetes, entre otras.
UY30282A1 (es) Compuestos quimicos
UY29839A1 (es) Ácidos fenoxiaceticos sustituidos, composiciones farmacéuticas conteniéndolos, procesos para su preparación y aplicaciones.
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
CO6361849A2 (es) Derivados de n-cicloalquil-nbifenilmetil-carboxamida fungicidas
UY29343A1 (es) Pirazolopiridinas y sales de las mismas, una composición farmacéutica que comprende dichos compuestos, un método para prepararlos y su uso.
NI201300072A (es) Derivados de heteroarilo como moduladores nachr alfa 7